Studying SYS6055 for aggressive B-cell lymphoma that returned
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an investigational drug, SYS6055, for people with an aggressive type of B-cell lymphoma that has come back or not responded to standard treatment. The goal is to see if the drug can help shrink tumors and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have aggressive B-cell lymphoma that is CD19-positive, meaning the cancer cells have a specific marker.
- Your lymphoma came back or did not get better after trying standard treatments.
- You have at least one measurable tumor, as seen on scans.
- You are fairly active and able to care for yourself (ECOG score 0 or 1).
- You agree to use effective birth control during the study and for 1 year after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental medicine (SYS6055 injection) for people with B-cell blood cancers (leukemia or lymphoma) that have come back or not responded to standard treatments. The goal is to see if it is safe and how well it works against cancer cells that have the CD19 marker.
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
This study tests a new experimental drug (called SYS6051) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if the drug is safe and how well it works, and it might help control your cancer.
This early-phase trial tests an experimental drug called STR-P004 in people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. The goal is to check the drug's safety and see if it helps shrink or control the lymphoma.
This study tests an experimental drug (GSK5926371) for people with a type of lymphoma (B-cell NHL) that has come back or not responded to earlier treatments. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
Hear when a new Relapsed/Refractory Aggressive B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.